Naives, Nonresponders, Relapsers: Who Is There Left to Treat?

Archita P. Desai, Nancy Reau

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.

Original languageEnglish (US)
Pages (from-to)483-495
Number of pages13
JournalClinics in liver disease
Issue number3
StatePublished - Aug 2011
Externally publishedYes


  • Epidemiology
  • Hepatitis C
  • Non-responders
  • Pegylated interferon
  • Relapse
  • Ribavirin

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Naives, Nonresponders, Relapsers: Who Is There Left to Treat?'. Together they form a unique fingerprint.

Cite this